First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
一线纳武利尤单抗联合伊匹木单抗治疗晚期非小细胞肺癌(CheckMate 568):以程序性死亡配体1和肿瘤突变负荷为生物标志物的疗效分析
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.18.01042
Ready, Neal; Hellmann, Matthew D; Awad, Mark M; Otterson, Gregory A; Gutierrez, Martin; Gainor, Justin F; Borghaei, Hossein; Jolivet, Jacques; Horn, Leora; Mates, Mihaela; Brahmer, Julie; Rabinowitz, Ian; Reddy, Pavan S; Chesney, Jason; Orcutt, James; Spigel, David R; Reck, Martin; O'Byrne, Kenneth John; Paz-Ares, Luis; Hu, Wenhua; Zerba, Kim; Li, Xuemei; Lestini, Brian; Geese, William J; Szustakowski, Joseph D; Green, George; Chang, Han; Ramalingam, Suresh S